A Phase I study of intratumoral administration of TDM-812 in patients with treatment-resistant breast cancer (RPN2siRNA)
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2017
At a glance
- Drugs TDM 812 (Primary)
- Indications Breast cancer
- Focus Adverse reactions; First in man
- 14 Sep 2017 Status changed from recruiting to discontinued.
- 13 Mar 2017 Planned End Date changed from 30 Sep 2017 to 31 Jan 2018.
- 20 May 2016 New trial record